About us

About

Long live the innovators.
We’re here to help – through thoughtful capital allocation and stewardship.

 

Innoviva was originally formed to maximize the value of the royalty streams coming from respiratory products co-developed with and licensed to GSK.

As these royalties grew, we began to focus more on capital allocation strategy to thoughtfully deploy our cash flows into areas of high unmet medical need with strong growth potential to create long-term value for shareholders and meaningfully improve patient outcomes.

Evolution of Innoviva

 
  • 1996
     

    NOVEMBER

    Incorporated in Delaware under the name Advanced Medicine, Inc.

     

    APRIL

    Changed its name to Theravance, Inc.

    2002
    2002
     

    NOVEMBER

    Innoviva / GSK collaboration agreement signed

     

    OCTOBER

    Breo launched in the US

    2013
    2014
     

    APRIL

    Anoro launched in the US

     

    JUNE

    Spun-off research and development operations

    2014
    2016
     

    JANUARY

    Rebranded to Innoviva, Inc.

     

    OCTOBER

    Trelegy launched in the US.

    2017
    2020
     

    JANUARY

    Armata* and Innoviva announced strategic investment

     

    JUNE

    Entasis and Innoviva announced private placement

    2020
    2021
     

    MAY

    Innoviva announced strategic repurchase of GSK’s equity stake

     

    MAY

     Announced acquisition of Entasis Therapeutics

    2022
    2022
     

    JULY

    Announced acquisition of La Jolla Pharmaceutical Company

     

    JULY

    Sold 15% stake in Theravance Respiratory Company**

    2022
    2023
     

    MAY

    Announced integration of Entasis and La Jolla into Innoviva Specialty Therapeutics

     

    MAY

    FDA approval of XACDURO®

    2023
    2023
     

    NOVEMBER

    Announced successful zoliflodacin Phase III results in uncomplicated gonorrhea

     

    DECEMBER

    Announced acquisition of U.S. commercial rights for ZEVTERA®

    2024
    2025
     

    JULY

    ZEVTERA® launched in the U.S.

     

    OCTOBER

    XACDURO® and ZEVTERA® nominated for 2025 Prix Galien USA Award

    2025
    2025
     

    DECEMBER

    FDA approval of NUZOLVENCE®


*Currently with greater than 50% equity ownership and significant warrant coverage by Innoviva

**Holder of Trelegy royalty rights

Our Core Values

 
COLLABORATE TO EXCEL.

We believe in the power of partnership and inclusiveness, and that the best ideas can come from anywhere in the room. Together we are always better.

BUILD TO LAST.

We take the long view and focus our efforts. We intend to endure the test of time and create lasting value for our shareholders, partners, and the world in which we live.

ACT WITH INTEGRITY, EVERY DAY IN EVERY WAY.

We believe in transparency, honesty, and trust. A genuine desire to do what’s right will always be what defines us as a team and guides us on our journey. 

MAKE OUR MARK BY MAKING A DIFFERENCE.

We believe the world will become a better place when we fuse our expertise, resources, and ambition with our passion for making a positive, lasting impact on people’s lives.

BE BOLD YET PRUDENT.

We believe in dreaming big, acting quickly and taking risks in line with our conviction yet managing them well.